{"url_path":"/sec/ew/8-k/2026-05-08/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1099800/0001099800-26-000028-index.html","accession_number":"0001099800-26-000028","cik":"0001099800","ticker":"EW","issuer_name":"Edwards Lifesciences Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1099800/0001099800-26-000028-index.html","primary_entity_key":"0001099800","primary_entity_name":"Edwards Lifesciences Corp"},"word_count":149,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers\n\nApproval of the Amended and Restated Long-Term Stock Incentive Compensation Program\n\nAt the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”). The amendment approved by stockholders included an increase in the total number of shares of Edwards common stock available for issuance under the Long-Term Stock Program by 7,000,000 shares to a new total share limit of 341,500,000 shares.\n\nThe complete terms of the Long-Term Stock Program amendment is qualified in its entirety by reference to the full text of the Amended and Restated Long-Term Stock Program, which is filed as Exhibit 10.1 to this Current Report on Form 8-K."}